Home
ORIC
ORIC News

Latest Oric Pharmaceuticals Inc. (ORIC) News on September 6, 2025

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 06/24/2025

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Zacks

3 months ago

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

Zacks

3 months ago

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

Zacks

3 months ago

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

JPMorgan biotech/pharma analysts hold analyst/industry conference call

TipRanks

3 months ago

JPMorgan biotech/pharma analysts hold analyst/industry conference call

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know

Zacks

3 months ago

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

Zacks

3 months ago

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

MT Newswires

3 months ago

Top Premarket Gainers

ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials

Insider Monkey

3 months ago

ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials

MT Newswires

3 months ago

ORIC Reports Preliminary Efficacy in Metastatic Prostate Cancer Study; Starts $125 Million Private Placement

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

GlobeNewswire

3 months ago

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

GlobeNewswire

3 months ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

GlobeNewswire

3 months ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

MT Newswires

4 months ago

Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

GlobeNewswire

4 months ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

4 months ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Insider Monkey

5 months ago

Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

5 months ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Simply Wall St.

5 months ago

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

GlobeNewswire

6 months ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

GlobeNewswire

7 months ago

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

7 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Oric Pharmaceuticals announces clinical supply agreement with Janssen

TipRanks

8 months ago

Oric Pharmaceuticals announces clinical supply agreement with Janssen

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

GlobeNewswire

8 months ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

GlobeNewswire

8 months ago

ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

8 months ago

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

9 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

GlobeNewswire

10 months ago

ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

10 months ago

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

10 months ago

JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target

MT Newswires

10 months ago

Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target

GlobeNewswire

10 months ago

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Simply Wall St.

a year ago

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire

a year ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

ORIC Pharmaceuticals Enters Discovery Collaboration With OpenBench

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

a year ago

ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

MT Newswires

a year ago

Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

GlobeNewswire

a year ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

Zacks

a year ago

ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

GlobeNewswire

a year ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

GlobeNewswire

a year ago

Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?

Insider Monkey

a year ago

Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Simply Wall St.

a year ago

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

GlobeNewswire

a year ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

a year ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%

Zacks

a year ago

How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%

GuruFocus.com

a year ago

ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

GlobeNewswire

a year ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares

GuruFocus.com

a year ago

ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

GlobeNewswire

a year ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

2 years ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

GlobeNewswire

2 years ago

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares

GuruFocus.com

2 years ago

ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares

Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why

Zacks

2 years ago

Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Andreas Halvorsen's Viking Global Investors LP Acquires New Stake in ORIC Pharmaceuticals Inc

GuruFocus.com

2 years ago

Andreas Halvorsen's Viking Global Investors LP Acquires New Stake in ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

IHOP launches pancake of the month deal

Restaurant Dive

2 years ago

IHOP launches pancake of the month deal

Tesla, Colgate-Palmolive, BrightSpring Health: Top Stocks

Yahoo Finance Video

2 years ago

Tesla, Colgate-Palmolive, BrightSpring Health: Top Stocks

In Bad News for IPO Market, BrightSpring Closes Below Offering Price

The Wall Street Journal

2 years ago

In Bad News for IPO Market, BrightSpring Closes Below Offering Price

The First of Long Island (FLIC) Matches Q4 Earnings Estimates

Zacks

2 years ago

The First of Long Island (FLIC) Matches Q4 Earnings Estimates

Associated Press Finance

2 years ago

Closing prices for crude oil, gold and other commodities

7 EV Stocks to Turn $100,000 Into $1 Million: January 2024

InvestorPlace

2 years ago

7 EV Stocks to Turn $100,000 Into $1 Million: January 2024

Reuters

2 years ago

UPDATE 1-UK to return looted royal regalia to Ghana in loan deal

Here's Why Kinross Gold (KGC) is a Strong Value Stock

Zacks

2 years ago

Here's Why Kinross Gold (KGC) is a Strong Value Stock

E2open Ocean Shipping Index Reflects Increase in Cross-Ocean Shipment Transit Times Due to Geopolitical Unrest and Natural Disasters

Business Wire

2 years ago

E2open Ocean Shipping Index Reflects Increase in Cross-Ocean Shipment Transit Times Due to Geopolitical Unrest and Natural Disasters

Partnership with Evolv Technology a Slam Dunk for Houston’s Toyota Center

Business Wire

2 years ago

Partnership with Evolv Technology a Slam Dunk for Houston’s Toyota Center

Amalgamated Financial Corp. Declares Regular Quarterly Dividend

GlobeNewswire

2 years ago

Amalgamated Financial Corp. Declares Regular Quarterly Dividend

4 Silver Mining Stocks to Watch Amid Industry Challenges

Zacks

2 years ago

4 Silver Mining Stocks to Watch Amid Industry Challenges

IGI to Release Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Business Wire

2 years ago

IGI to Release Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

2 years ago

Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why

Target Hospitality Announces Senior Level Promotions

PR Newswire

2 years ago

Target Hospitality Announces Senior Level Promotions

Trump-Tied SPAC Surges 175% in Six-Day Rally

Bloomberg

2 years ago

Trump-Tied SPAC Surges 175% in Six-Day Rally

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

GlobeNewswire

2 years ago

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Ecovyst Provides Update on Plans for Expansion of Orange, Texas, Catalyst Activation Facility

PR Newswire

2 years ago

Ecovyst Provides Update on Plans for Expansion of Orange, Texas, Catalyst Activation Facility

Genco Highlights Steps the Company Is Taking to Drive Sustainable, Long-Term Shareholder Value

GlobeNewswire

2 years ago

Genco Highlights Steps the Company Is Taking to Drive Sustainable, Long-Term Shareholder Value

Eaton Vance Tax Advgd Gbl Div Inc Fd's Dividend Analysis

GuruFocus.com

2 years ago

Eaton Vance Tax Advgd Gbl Div Inc Fd's Dividend Analysis

Share on Social Networks: